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Abstract. Pancreatic/3-cells and 3,-aminobutyric a id 
(GABA)-secreting neurons both express the enzyme 
glutamic acid decarboxylase (GAD) which is a major 
target of autoantibodies a sociated with/S-cell destruc- 
tion and impairment of GABA-ergic neurotransmitter 
pathways. The predominant form of GAD in pancreatic 
/s-cells, GAD65, is synthesized as a soluble hydrophilic 
molecule, which is modified to become firmly mem- 
brane anchored. Here we show by immunogold elec- 
tron microscopy that GAD65 is localized to the mem- 
brane of small vesicles which are identical in size to 
small synaptic-like microvesicles in pancreatic/~-cells. 
The NH2-terminal domain of GAD6~ is the site of a 
two-step modification, the last of which results in a 
firm membrane anchoring that involves posttranslational 
hydroxylamine sensitive palmitoylation. GAD65 can be 
released from the membrane by an apparent enzyme 
activity in islets, suggesting that the membrane an- 
choring step is reversible and potentially regulated. 
The hydrophobic modifications and consequent mem- 
brane anchoring of GAD65 to microvesicles that store 
its product GABA may be of functional importance 
and, moreover, significant for its selective role as an 
autoantigen. 
T 
hE 3,-aminobutyric acid (GABA)~-synthesizing en- 
zyme glutamic acid decarboxylase (GAD) is ex- 
pressed at comparable vels in GABA-secreting neu- 
rons and in pancreatic/s-cells in the islets of Langerhans 
(Okada et al., 1976). GABA is a major inhibitory neuro- 
transmitter inthe CNS, whereas its function in islets remains 
elusive. The expression of GABAA receptors on the glucagon 
producing o~-cells in islets (Rorsman et al., 1989) suggests 
that GABA may play a role in paracrine signaling within the 
islet. GAD has been identified as the 64-kD autoantigen of 
the/s-cells (Baekkeskov et al., 1990), to which autoanti- 
bodies arise concomitant with/s-cell destruction and the de- 
velopment of insulin-dependent diabetes mellitus (IDDM) 
0]aekkeskov etal., 1982, 1987; Atldnson et al., 1990). Fur- 
thermore, GAD in neurons is an autoantigen in stiff-man 
syndrome, a rare neurological disease characterized by a 
high coincidence with IDDM (Solimena et al., 1990). The 
Steinunn Baekkeskov's current address is Hormone Research Institute and 
the Departments of Microbiology/Itranunology and Medicine, University 
of California, San Francisco, CA 94143-0534. Correspondence should be 
addressed to Steinunn Baekkeskov. 
1. Abbreviations used in this paper: GABA, 3,-aminobutyric a id; GAD, 
glutamic acid decarboxylase; IDDM, insulin dependent diabetes mellitus; 
PIG, phospatidyl inositol glycan; PIPLC, phosphatidyl inositol-specific 
phospholipase C; RP-HPLC, reverse phase high pressure liquid chromatog- 
raphy; S1, First cytosol fraction; $2, second cytosol fraction; SMS, stiff- 
man syndrome; TX-114, Triton X-114; WP, washed particle fraction. 
reasons for the unusual susceptibility ofthe GAD molecule 
to becoming an autoantigen are unclear, and their elucida- 
tion is a major goal. Neurons express two GAD proteins en- 
coded by two distinct genes. The proteins differ mainly in the 
first 100 amino acids, but share extensive homology in the 
remainder of the molecules (Erlander et al., 1991). 
We have identified two GAD proteins in pancreatic/s-cells 
03aekkeskov etal., 1990; Christgau et al., 1991). The larger 
65-kD protein, which is expressed atlow levels in rat islets, 
is hydrophilic and soluble throughout i s lifetime and was 
shown to be identical to the larger GAD protein in brain 
(Christgau et al., 1991). This protein is now called GAD67 
(also called GAD-1 and previously GADs). The smaller 
64-kD protein, which is the major GAD protein in/s-cells, 
was shown to be identical to the smaller GAD protein in 
brain, with regard to antigenic epitopes, size and charge 
(Christgau et al., 1991). A comparison of the primary struc- 
ture of the smaller GAD protein in islets (Karlsen et al., 
1991) and the smaller GAD protein in brain (Bu et al., 1992) 
shows that they are identical. This protein is now called 
GAD~ (also called GAD-2 and previously GADs). GAD65 
is also synthesized as a hydrophilic and soluble molecule but 
matures into a firmly membrane anchored protein in a pro- 
cess that seems to involve two steps (Christgau et al., 1991). 
The first step results in a hydrophobic molecule which is 
soluble or has a low membrane avidity. The second step 
results in membrane anchoring. Thus three distinct forms of 
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GAD65 can be detected in pancreatic/3-cells, a hydrophilic 
soluble form, a hydrophobic form that is soluble or has a low 
membrane avidity, and a firmly membrane-bound form that 
can only be released from membranes by detergent, and thus 
has the characteristics of an intrinsic membrane protein. The 
maturation of GAD65 does not involve detectable changes in 
size or charge, which suggests that membrane anchoring 
may be mediated by a small lipid (Christgau et al., 1991). 
Although antibodies in many diabetic and stiff-man syn- 
drome patients recognize both GAD67 and GAD65 in their 
native configuration, the incidence of antibodies to GAD65 
is significantly higher than to GAD67 (our unpublished 
results). Furthermore, GAD65, but not GAD67, possesses a 
primary structure pitope or epitopes that are recognized by 
stiff-man syndrome antibodies but not by IDDM antibodies 
(Baekkeskov et al., 1990). Thus GAD65 has autoantigenic 
properties that clearly set it aside from GAD67 and that may 
be related to its subcellular targeting to membrane compart- 
ments. GAD is an intracellular enzyme, but its exact subcel- 
lular localization is not known. Immunohistochemical st in- 
ing and confocal microscopy analysis of neurons and/s-cells 
showed colocalization ofGAD with GABA and synaptophy- 
sin, a marker protein for synaptic vesicles (Reetz et al., 
1991). Such studies have also demonstrated the localization 
of GAD and GABA to a vesicular compartment, which is 
clearly distinct from the insulin secretory granules in/s-cells 
(Sorenson et al., 1991; Reetz et al., 1991) and which was ten- 
tatively identified as synaptic vesicles in neurons and synap- 
tic like microvesicles in /3-cells (Reetz et al., 1991). Im- 
munoperoxidase EM of brain sections and immunogold EM 
of brain and islet cell homogenates u ing GAD antibodies 
however did not show GAD immunoreactivity in synaptic 
vesicles but rather localized GAD to the cytoplasm and in 
the proximity of synaptic vesicles in neurons and around 
membranes of pleomorphic microvesicles of tubular and 
cisternal elements, as well as throughout the cytoplasm in 
pancreatic/S-cells (Wood et al., 1976; Reetz et al., 1991). 
Furthermore, GAD could not be recovered on synaptic vesi- 
cles or synaptic-like microvesicles nor in other membrane 
compartments after subcellular fractionation (Reetz et al., 
1991). The EM analysis and the subcellular fractionation 
data are consistent with the localization of GAD67 in the 
cytoplasm, but raise questions about the subcellular local- 
ization of the membrane bound GAD65. 
In this report we have analyzed the subcellular localization 
of GAD65 in intact islets by immunogold EM. Furthermore, 
we have characterized the hydrophobic membrane anchoring 
domain in the GAD65 molecule and addressed the question 
of whether GAD6s is modified by one or more of the lipid 
moieties which are known to mediate membrane anchoring 
of proteins, i.e., phosphatidylinositolglycan (PIG) poly- 
isoprenyl groups, and/or fatty acids (Sefton and Buss 1987; 
Hancock et al., 1989; Casey et al., 1989). We present evi- 
dence that GAD65 is anchored to the membrane of vesicles, 
which are likely to be the synaptic-like microvesicles in 
/3-cells, and that membrane anchoring is achieved by a post- 
translational hydroxylamine-sensitive palmitoylation i the 
NH2-terminal region of the molecule where GAD65 differs 
significantly from GAD67. The membrane anchoring is re- 
versible, which may reflect he possibility of controlling the 
amount of the protein in membrane compartments. 
Materials and Methods 
Antibodies 
$3, a sheep antiserum raised to purified rat brain GAD (Oertel et al., 1980), 
was a gift from I. Kopin (National Institutes of Health). The GAD6 mAb 
(Chang and Gottlieb, 1988) was a gift from D. Gottlieb (Washington 
University, St. Louis, MO). A polyclonal rabbit antibody (1266) raised 
against asynthetic peptide containing the carboxyl-terminal sequence of rat 
GAD67 (Cys-Thr-Gln-Ser-Asp- Ile-Asp-Phe-Leu -Ile-Glu-Glu-Ile-Glu-Arg- 
Leu-Gly-Gln-Asp-Leu) (Wyborski et al., 1990) was a gift from J. S. Peter- 
sen (Hagedorn Research Laboratory, Gentofte, Denmark). Sera from IDDM 
patients with high titers of GAD autoantibodies have been described earlier 
(Baekkeskov et al., 1989). 
Isolation of Islets and Biosynthetic Labeling 
Rat islets were used in all experiments described in this study except hat 
biosynthetic labeling with 3H-fatty acids was also carried out using human 
islets. Isolation of human and rat islets, maintenance in culture and radioac- 
tive labeling with 135S]methionine for 4 h was carried out as described 
(Baekkeskov et al., 1989). For biosynthetic labeling with fatty acids, islets 
were washed twice by centrifugation i  DME containing 16 mM glucose 
and supplemented with 5 mM Na-pyruvate, 5 mg/ml fatty acid free BSA, 
100 U/ml penicillin, 100/,tg/ml streptomycin, and nonessential amino acids 
(FA medium). Islets were labeled for 4 h at 37~ in the same medium con- 
taining either (9, 10) 3H-palmitic acid or (9, 10) 3H-myristic acid (50-60 
Ci/mmol, Amersham Corp., Arlington Heights, IL) at 800 #Ci/ml. In ex- 
periments o analyze ffect of emetine in labeling experiments, i lets were 
preincubated with 10 p,M emetine followed by [35S]methionine labeling for 
4 h in the presence of 10 #M emetine. Similarly in experiments with 
mevinolin (a kind gift from Dr. A. W. Alberts, Merck, Sharp, and Dohme 
Research Laboratories, Rahway, NJ), islets were preincubated for 1 h with 
10, 20, 30, 40, or 50 #M mevinolin and then labeled for 4 h with [3~S]me- 
thionine in the presence of the same concentrations of mevinolin. For bio- 
synthetic labeling with 3I-l-mevalonic acid, islets were preincubated for 1 h 
with 50 #M mevinolin in FA medium and labeled with 3H-mevalono lac- 
tone (36 Ci/mmol, New England Nuclear DuPont Co., Wilmington, DE) 
at 250 #Ci/ml for 4 h. Islets were also labeled with 3H-myoinositol (90.5 
Ci/mmol, Amersham Corp.), 3H-ethanolamine (40 Ci/mmol, Amersham 
Corp.) and 3H-glucosamine (32 Ci/mmol, Amersham Corp.) for 6 h in 
RPMI 1640 containing 16 mM glucose and supplemented with 1% FCS, 
0.5 % human serum, 100 U/ml penicillin, 100 #g/ml streptomycin, and iso- 
tope at 200 #Ci/ml. Labeled islets were harvested by centrifugation, washed 
twice in nonradioactive medium and once in 20 mM Hepes, pH 7.4, 150 
mM NaC1 and 10 mM benzamidine/HC1, and then either immediately 
processed for homogenization a d isolation of soluble and particulate frac- 
tions or snap frozen and stored in aliquots at -80~ 
Expression of GAD6~ in Sf9 Insect Cells 
Recombinant GAD~ baculovirus vectors were constructed by ligating a 
2.4-kb EcoRI fragment of rat GAD65 cDNA clone pGAD-92 (a kind gift 
from Dr. A. Tobin, UCLA) into the EcoRI site of the baculovirus transfer 
vector pVL1392 (Invitrogen, San Diego, CA). Clone pGAD-515 containing 
the sense orientation for GAD65 was used in a calcium phosphate cotrans- 
fection with wild-type Autographa californica nuclear polyhedrosis virus. 
Recombinant viruses were then isolated as described (Summers and Smith, 
1987). For radiolabeling of GAD65 in insect cells, Spodopterafrugiperda 
St9 cells were infected with recombinant baculovirus. 48 h later the cells 
were labeled for 4 h with either 3H-palmitate, 3H-myristate, 3H-meva- 
lonolactone at 800/~Ci/ml, or 35S-methionine at 80 ttCi/ml as described 
above for islets, except hat labeling was in Grace medium. 
Fractionation of Islets and Sf9 Cells 
Separation ofsoluble and membrane-bound fractions was carried out by two 
methods described in detail previously (Christgau et al,, 1991; Baekkeskov 
et al., 1990). The first method involves homogenization i  an isotonic 
Hepes/sucrose buffer (10 mM Hepes/NaOH, pH 7.4, 0.25 M sucrose, 10 
mM benzamidine/HCl, 0.1 mM p-chloromercuribenzene sulfonic acid and 
0.25% Trasylol) (Christgau et al., 1991) followed by ultracentrifugation at 
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100,000 g or higher for 1 h to separate a crude particulate and a cytosol 
(St) fraction. The crude particulate fraction is then resuspended in Hepes 
buffer A (10 mM Hepes/NaOH, pH 7.4, 150 mM NaC1, 10 mM benzami- 
dine/HCl, 0.25% Trasylol, 0.1 mM P-chloromercuribenzene sulfonic acid 
and 0.1 mM Na3VO4) followed by ultracentrifugation at 100,000 g or 
higher for 1 h resulting in a new c)'tosol fraction, $2, and a washed particu- 
late fraction, WP. The SI fraction prepared by this method contains mainly 
GAD67 and the hydrophilic soluble form of GAD65. The crude particulate 
fraction contains both a hydropbobic firmly membrane anchored GAD65 
and hydrophobic GADss which is either soluble or has a low membrane 
avidity. The two hydrophobic GAD65 forms separate into the WP and $2 
fractions, respectively (Christgau et al., 1991). The second method uses 
homogenization in a hypotonic Hepes buffer (10 mM Hepes/NaOH, pH 7.4, 
1 mM EGTA, 1 mM MgC12, 1 mM aminoethylisothiouronium bromide 
hydrobromide, and 0.2 mM pyridoxal 5'-phosphate (Hepes buffer B) (Baek- 
keskov et al., 1990), followed by ultracentrifugation at 100,000 g or higher. 
The hypotonic onditions result in release of most of the hydrophobic, solu- 
ble, or low membrane avidity GAD65 form into the cytosol and combine 
in one fraction the soluble forms of GAD65. The membrane fraction con- 
tains the firmly membrane-anchored hy rophobic GAD65 form which can 
only be released by detergents. 
Proteins were extracted from the particulate fractions with 1% Triton 
X-114 (TX-114) in either Hepes buffer A or B, as described (Baekkeskov 
et al., 1990; Christgau et al., 1991). 
TX-114 Partitioning Assays 
TX-114 detergent phase separations ofdetergent extracts of particulate frac- 
tions or of soluble fractions after addition of TX-114 were performed ac- 
cording to Bordier (1981) (Baekkeskov et al., 1989). For comparative analy- 
ses of the amphiphilic properties of GAD65 in different fractions, buffer 
compositions were adjusted to obtain identical conditions in each fraction. 
Experiments with Phosphatidyl Inositol-specific 
Phospholipase C 
The phosphatidyl inositol-specific phospholipase C (PIPLC) used for these 
experiments was either from Bacillus thuringiensis (a kind gift from Dr. M. 
Low, The Rockefeller University, New York) or Bacillus cereus (Boehringer 
Marmheim Corp., Indianapolis, IN), Islets were homogenized in isotonic 
Hepes buffer and the P-100 fraction washed twice by resuspension and 
ultracentrifugation f llowed by resuspension a d incubation for 30, 60, or 
120 min at 0, 13, 24, and 37~ in the presence or absence of PIPLC at con- 
centrations ranging from 125 mU/ml to 5 U/mt. Experiments were per- 
formed using three different buffer compositions for washings of the P-100 
fraction and the incubations with and without PIPLC. Hepes buffer C was 
10 mM Hepes/NaOH, pH 7.4, supplemented with 0.25% Trasylol. Hepes 
buffer D was I0 mM Hepes/NaOH, pH 7.4, supplemented with 10 ~g/ml 
pepstatin A, 20 tzg/ml leupeptin, 10 tzg/ml antipain, and 0.01% Trasylol. 
Buffer E was 10 mM Tris/HC1, pH 7.5, 0.25 M sucrose, 5 mM PMSF, 5 
mM iodoacetate, 1 mM leupeptin, and t00/zM N-a-p-tosyl-L-lysine chlo- 
romethyl ketone. Hepes buffer A was used for control incubations. 
Immunochemical Analysis and Gelelectrophoresis 
SDS-PAGE, immunoprecipitation, a dimmunoblotting were performed as 
described (Baekkeskov et al., 1989, 1990; Christgau et al., 1991). 
Chemical Analysis of the Fatty Acid Group 
For reverse phase high pressure liquid chromotography (RP-HPLC) analy- 
sis of covalently bound fatty acids, 3H-palmitate-labeled GAD65 was ex- 
cised from SDS-gels and the gel pieces were incubated for 2 h at 30~ in 
1.5 M NaOH in 20% methanol to release fatty acids followed by pentane 
extraction to remove neutral lipids. The reaction mixture was acidified with 
HC1 and fatty acids extracted into pentane. The free fatty acids isolated 
from GAD65 and cold standards were derivatized to their corresponding 
phenacyl esters according to Wood and Lee (1983), and analyzed on an AI- 
tex C-18 ultrasphere reverse phase HPLC column. Bound material was 
eluted with a linear gradient of 75-100% acetonitrile. Absorbance at 242 
nm and cpms were measured inthe eluted fractions. For RP-HPLC analysis 
of total fatty acids in St9 cells, the membrane fraction was extracted with 
chloroform ethanol, hydrolyzed, and analyzed as described above. Peaks 
were identified by comparison with the retention time for cold fatty acid 
standards carried along through the derivatization procedure. 
Tryptic Cleavage of GAD 
TX-114 detergent phase purified particulate and soluble fractions prepared 
in hypotonic Hepes buffer were diluted to 1% TX-114 and incubated with 
and without rypsin as described (Baekkeskov et al., 1990) followed by a 
renewed phase separation and analysis of aqueous and detergent phases by 
immunoblotting. To analyze the ability of trypsin to release GAD65 from 
membranes, aliquots of P-100 were prepared, washed two times in Hepes 
buffer B, resuspended in 200/~1 of the same buffer, and incubated for 1 h 
at 25~ in the presence or absence of 4.0 U trypsin (Sigma Chem. Co., St. 
Louis, MO). The trypsin digestion was terminated by placing the samples 
on ice and adding 1/10 vol of 10 mM Hepes/NaOH, pH 7.5, 5 mM benzami- 
dine/HCt, 5 mM EDTA, 5 mM Na4P207, and 1/10 vol of 1 mg/ml soya 
bean trypsin inhibitor in water. Particulate material was sedimented by 
ultracentrifugation at 265,000 g. Released material and particulate extracts 
were subjected to TX-114 phase separation followed by Western blot analy- 
sis of GAD in the different fractions. 
Spontaneous Release of GAD~s from 
Membrane Fractions 
Islets were homogenized in 10 mM Hepes, 150 mM NaCt, pH 7.4 (Hepes 
buffer F). The P-100 particulate fraction was washed twice in the same 
buffer and separated into aliquots. Membrane aliquots were resuspended in 
either Hepes buffer F or in the same buffer supplemented with 0.1 mM 
PCMBS, 5 mM EDTA, 0.25% trasylol, 5 mM NaF, I0 mM benzami- 
dine/HC1, 0.1 mM NaaVO4, pH 7.4, and incubated for 5, 15, 45, and 75 
min at 25~ respectively, followed by centrifugation at265,000 g for 30 
min and analysis of released material by Western blotting. 
Electron Microscopy 
Immunogold electronmicroscopy was performed on neonatal rat islets, 
which had been maintained in culture for 3-5 d. Islets were fixed for 6 h 
in 4 % paraformaldehyde, 0.1% glutaraldebyde in 100 mM cacodylate buffer 
containing 0.2 mM CaCI~, and 4% sucrose. Islets were postfixed for 15 
min in 1% OsO4, 1.5% ferricyanide in 0.1 M 2,4,6-trimethylpyridine a d
for 30 min in 2% aqueous uranyl acetate. Dehydration and embedding in
LR White resin (medium hardness; Polysciences Inc., Warrington, PA) was 
performed as described (Newman et al., 1983). 50-nm sections were cut 
on a Ultracut E microtome (Reichard Jung, Deerfield, IL) and placed on 
grids. Antibody incubation was for 18 h with the GAD antiserum 1266 or 
$3 (dilution 1:100) followed by incubation with appropriate 10-rim gold- 
conjugated secondary antibodies (E-Y Labs., San Mateo, CA). Control 
grids were stained with normal sheep or rabbit serum followed by the sec- 
ondary antiserum or with secondary antiserum only. Grids were coated with 
formvar and viewed on a JEOL-100C transmission electron microscope at 
60 kV. ~cells as well as non-B-cells (a-cells, exocrine cells) were viewed 
on each grid and subjected to quantitative analysis by counting the gold par- 
ticles. ~-cells and exocrine cells did not differ significantly in total gold par- 
ticle counts and a-cells were selected as control cells for further subcellular 
analysis. Gold particles were counted in 19/3-calls on 19 different grids 
representing 4 different islet isolations and in 7 adjacent a-cells stained with 
the 1266 antibody. 1821 gold particles were detected in the B-cells, giving 
95.8 + 17 (mean + SD) particles per B-cell. The a-cell counts revealed 
226 particles or 32.3 + 4.7 particles per a-cell. As a control six B-cells (227 
particles, 41.3 + 2.5 per B-cell) and five adjacent a-cells (165 particles, 33 
• 4.7 per a-cell) were counted on six grids stained with normal rabbit se- 
rum. Cells were divided into the following subcellular areas during the 
quantitative analysis: small vesicles of diameter 30-60 nm (49.6 5: 17.6, 
mean + SD), ER/Golgi, other membranes (including plasma membranes 
and unidentified membranes), cytoplasma, nuclei, large dense core vesicles 
(insulin or glucagon secretory vesicles), mitochondria/other (other = 
unidentified subcellular structures). The mean values for each fraction ob- 
tained with the 1266 serum were corrected by subtraction of mean values 
obtained with the nonimmune serum and the pooled standard eviations 
calculated. 
Results 
GADs5 Is Localized to the Membrane of Small Vesicles 
To analyze the subcellular localization of GADe, sections 
of fixed and embedded rat islets were sectioned and sub- 
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Figure 1. Electron micrographic analysis of GAD expression in 
pancreatic islet cells. (A and B) Micrographs of ~-cell areas show- 
ing the localization of GAD by an immunogold abeling technique. 
The sections shown in A and B were stained with the $3 antiserum 
to GAD. Some microvesicles with a clear core (V) show GAD 
staining in the membrane. Insulin-containing secretory granules (i) 
are characterized bya typical halo around adense granule core. Mi, 
mitochondrion. (C) Quantitative analysis of the localization of 
GAD in different subcellular areas of/3 (black bars) and c~-cells 
(shaded bars) on electronmicrographs subjected to immunogold a- 
beling using the 1266 antiserum to GAD. N~p is the corrected 
number of gold particles obtained by subtracting nonimmune se- 
rum values from those produced with the GAD specific 1266 an- 
tiserum as described in Materials and Methods. SD is indicated on 
the bars. SMLE small vesicles 30-60 nm in diam; LDCI~, large 
dense core vesicles which secrete insulin or glucagon; ER/G, ER 
and Golgi membranes; O/M, other nonidentified membranes and 
plasma membranes; Cyt, Cytoplasm; Nuc, Nuclei; Mit/O Mito- 
chondria nd nonidentified subcellular structures. Bars, 240 nm. 
jected to immunogold staining using both the $3 antiserum, 
which has a high immunoreactivity o GAD65 but reacts 
only weakly with GAD67 in immunoprecipitation experi- 
ments and on Western blots (results not shown), and the 1266 
antiserum, which recognizes both forms (Christgau et al., 
1991). The specificity of EM immunogold labeling of fixed 
and embedded tissue with both antisera was high and the sen- 
sitivity low (Fig. 1). The predominant immunolabeling for 
GAD with either antiserum was in the membrane of small 
vesicles (30-60 nm in diam) in/3-cells (Fig. 1, A-C). The 
specificity of this localization is illustrated by the number of 
gold particles detected in this compartment in ~-cells im- 
munolabeled with the 1266 antiserum (29.7 + 6.6 parti- 
cles/cell, mean + SD) which was '~60-fold higher than the 
labeling of comparable small vesicles in co-cells (0.4 + 0.7 
particles/cell), and 60-75-fold higher than nonspecific label- 
ing of small vesicles in /3- and c~-cells produced with a 
nonimmune serum (0.5 + 0.8 particles/cell and 0.4 + 0.5 
particles/cell, respectively). The gold particles in/3-cells la- 
beled with nonimmune serum and in or-cells labeled with 
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either GAD antiserum or noninunune serum were concen- 
trated in the cytoplasm, mitochondria, nd nuclear fractions. 
The results of a quantitative analysis of electronmicrographs 
immunolabeled with the 1266 antiserum and corrected for 
background immunolabeling with nonimmune serum (Fig. 
1 C) indicate that •50% of the specific immunolabeling for 
GAD in/3-cells is localized to the membrane of the small 
vesicles, 18% is found in insulin secretory granules, 14% in 
ER/Golgi membranes, 12% in other membranes (unidenti- 
fied membranes and plasma membranes), and 6% in the cy- 
toplasm. The low level of specific GAD immunolabeling in
the cytoplasm of ~-cells is consistent with the low level of 
cytosolic GAD67 protein in these cells and with the majority 
of the GAD65 protein being membrane associated (Christ- 
gau et al., 1991). The specific GAD immunolabeling in in- 
sulin granules was detected in the perigranular space but 
not in the dense insulin core. The gold particles ometimes 
formed characteristic circular structures of 30-60 nm in di- 
ameter just inside the insulin secretory granule membrane 
(results not shown) suggesting that they represent small vesi- 
cles that have fused with the insulin granule. This result, 
which merits further investigation, suggests that the small 
GAD-positive vesicles can fuse with and perhaps release 
GABA into the insulin secretory granules. The specific GAD 
immunolabeling in all compartments was restricted to 
~-cells. Thus the number of gold particles in u-cells (Fig. 
1 C) and exocrine cells (results not shown) was not sig- 
nificantly different from background immunolabeling with 
nonspecific serum, which is consistent with the/3-cell spe- 
cific expression of GAD (Okada et al., 1976; Baekkeskov et 
al., 1990; Sorensen et al., 1991). The results provide evi- 
dence that GAD65 is predominantly ocalized to the mem- 
brane of microvesicles in the pancreatic/3-cell. The small 
vesicles are clearly distinct from the insulin granules in those 
cells (Fig. 1) and are likely to be the synaptic-like microvesi- 
cles containing GABA which have been described in/3-cells 
(Reetz et al., 1991). This result raises questions of the mech- 
anism by which this subcellular localization is achieved. The 
following sections characterize the membrane anchoring of 
GAD65. 
Palmitoytation Distinguishes Membrane-bound and 
Soluble Forms of GAD~j 
Depending on the conditions by which islets of Langerhans 
are homogenized and separated into soluble and particulate 
fractions, hydrophilic soluble GAD~ (Sl-form) and hydro- 
phobic soluble or low membrane avidity GAD65 (S2-form) 
can either be released simultaneously (in hypotonic Hepes 
homogenization buffer), or sequentially (in isotonic Hepes/ 
sucrose homogenization buffer followed by resuspension of
a crude particulate fraction in an isotonic Hepes buffer and 
resedimentation f membranes toform WP). The hydropho- 
bic membrane-anchored GAD6~ (WP-form) can, in both 
conditions, only be released from the particulate fraction by 
detergent (Christgau et al., 1991 and results not shown). 
Two-dimensional gel electrophoretic analyses of the mem- 
brane-anchored and soluble GAD65 forms has not revealed 
any differences in size or charge between the different forms 
(Christgau et al., 1991), suggesting that the hydrophobic 
modification and membrane anchoring is mediated by a fatty 
acid or a small neutral ipid. 
To assess the possibility that GAD6~ contains fatty acids 
either covalently linked to the protein backbone or as a part 
of a larger lipid structure, human and rat islets were labeled 
for 4 h with either 3H-palmitic acid or 3H-myristic acid at 
the same specific activity. Islets were homogenized in iso- 
tonic conditions and the two cytosolic fractions, S1 and $2, 
and the washed WP were prepared. GAD6~ was isolated by 
immunoprecipitation a d analyzed by SDS-PAGE and fluo- 
rography (Fig. 2). The incorporation of radioactivity was de- 
tected in GAD65 immunoprecipitated from detergent lysates 
of whole human islets (results not shown) and only in the 
washed membrane fractions but not the cytosolic S1 and $2 
fractions of rat islets labeled with 3H-palmitic acid (Fig. 2). 
Incorporation of radioactivity into GAD6~ was not detected 
in experiments with 3H-myristic acid (results not shown). 
The absence of label in background bands and in soluble 
forms of GAD6~ in the immunoprecipitates from 3H-pal- 
mitic acid-labeled material (Fig. 2) suggested that the incor- 
poration of tritium into membrane-bound GAD6s was not 
due to conversion of label to radioactive amino acids. Thus 
the results suggest that palmitic acid itself or a lipid deriva- 
tive of palmitate is covalently linked to the membrane an- 
chored but not the soluble forms of GAD6~ and is involved 
in the membrane anchoring of the enzyme. 
Palmitoylation fGAD65 Is a Posttranslational Event 
Palmitoylation of some cellular proteins is greatly reduced 
when protein synthesis i  inhibited, indicating that acylation 
in these cases is cotranslational (Magee and Courtneidge, 
1985; Olson et al., 1985). In contrast, acylation of other pro- 
teins, including p21 N-ras (Magee et al., 1987), GAP 43 
(Skene and Virag, 1989), and others (Olson and Spizz, 
1986), is unaffected by these inhibitors, showing that acyla- 
tion of these proteins is posttranslational. Toassess whether 
the incorporation of radioactivity into membrane-anchored 
GAD6~ in the presence of 3H-palmitic acid is dependent on 
protein synthesis, we analyzed the effect of emetine, an in- 
hibitor of protein biosynthesis (Fig. 2 B). The presence of 
10/~M emetine did not inhibit incorporation of radioactivity 
into membrane-anchored GADs5 in labeling experiments 
with 3H-palmitic acid (Fig. 2 B, compare lanes 4 and 7), 
despite inhibiting [35S]methionine incorporation >90%. 
This result shows that the labeling of the membrane- 
anchored GAD65 in the presence of 3H-palmitic acid is a 
posttranslational event independent ofprotein synthesis and 
excludes the possibility that the protein is labeled by biosyn- 
thetic incorporation of 3H amino acids derived from palmi- 
tate. The data do not, however, exclude the possibility that 
GAD~ is modified posttranslationally b a lipid derivative 
of palmitate. 
GAD Is Palmitoylated in Sf9 Insect Cells 
Sf9 insect cells have been shown to correctly modify ex- 
pressed proteins with both palmityl (Lanford, 1988), myris- 
tyl (Gheysen et al., 1989), and isoprenyl moieties (Khosravi- 
Far et al., 1991). Since GAD~ is a rare protein in pancreatic 
~-cells (Baekkeskov et al., 1989), and since the autoradio- 
graphic detection of 3H is very insensitive, we assessed 
whether ecombinant GAD65 expressed at high levels in Sf9 
cells could be used to further characterize 3H-palmitate-la- 
beled GADs5. GAD65 was distributed in soluble and mem- 
brane-bound fractions in Sf9 cells, much as in pancreatic 
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Figure 2. Posttranslational incorporation ofpalmitic acid into membrane-bound but not soluble forms of GAD6~. (A) Radioactive labeling 
of membrane bound GAD65 in the presence of 3H-palmitic acid. Rat islets were labeled in the presence of 3H-palmitic acid for 4 h and 
subjected to homogenization in isotonic conditions to prepare a cytosolic (S1) and a crude membrane fraction. The crude membrane frac- 
tion was washed by resuspension a d centrifugation resulting in a supernatant ($2) containing mainly cytosolic proteins and WP fractions. 
The S1 fraction (lanes 6 and 7), was concentrated fivefold and subjected to immunoprecipitation t gether with 2/3 of the $2 (lanes 4 and 
5) and 1/3 of the WP fraction (lanes 6 and 7) to obtain similar levels of GAD65 in each fraction. Immunoprecipitation was performed 
first with control serum (C) (lanes 3, 5 and 7) and then with IDDM serum (I) (lanes 2, 4, and 6). Immunoprecipitates were analyzed 
by SDS-PAGE in modified Laemmli buffers followed by fluorography. A short exposure to visualize [35S]methionine-labeled GAD67 and 
GAD65 components immunoprecipitated from the SI fraction of 1,000 islets is shown in lane 1. Note that GAD65 splits into two compo- 
nents r and ~, which have been shown to be identical with regard to all parameters analyzed except mobility on SDS-PAGE. (B) Effect 
of emetine on incorporation of radioactivity into membrane-bound GAD~ in the presence of palmitic acid. Rat islets were preincubated 
in FA medium either with or without 10 nM emetine for 1 h and then labeled with 3H-palmitic acid in the same medium for 4 h. Aliquots 
of rat islets were incubated in parallel with or without emetine and labeled with [35S]methionine. S1, $2, and WP fractions were prepared, 
immunoprecipitated with IDDM serum (I), and analyzed by SDS-PAGE in modified Laemmli buffers and fluorography. Fluorography 
shown for [3SS]methionine-labeled proteins was for 14 d with emetine (lanes 1, 2, and 3), at which time lanes without emetine were com- 
pletely black (not shown). Fluorography for 3H-labeled proteins with (lanes 4-6) and without emetine (lane 7) was for 3 mo. Note that 
in this experiment the GAD65 ~ component is more pronounced than a in lanes 2, 3, 4, and 7. The position of molecular mass markers 
is indicated in kilodaltons. 
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Figure 3. Cellular localization and hydroxylamine sensitivity of 3H palmitate labeled GAD~s in Sf9 ceils. Sf9 cells were infected with bac- 
ulovirus containing therat GAD~ eDNA and grown in the presence of either [35S]methionine or 3H-palmitic acid and separated into a 
eytosolic and a membrane fraction after homogenization in hypotonic conditions. Cytosol and membrane fractions from 3H-palmitic 
acid-labeled islets were immunopreeipitated with either the GAD6 mAb oran irrelevant mAb (C). Immunoprecipitates were divided into 
three equal size aliquots and analyzed i  triplicate by SDS-PAGE (lanes 2 -5,10--13, and 18-21 ) inparallel with an aliquot of nonimmunopre- 
cipitated eytosol and membrane fractions of 3H-palmitate-labeled material (lanes 7, 8, 15,16, 23, and 24) and an immunoprecipitate of 
a [35S]methionine-labeled membrane fraction (lanes 6, 14 and 22). The triplicate gels were either untreated or incubated in either 1 M 
hydroxylamine, pH 8, or 1 M "Iris, pH 8, before processing for fluorography. Molecular mass markers indicated in kllodaltons are shown 
in lanes 1, 9, 17, and 25. 
~-cells. Again, as in #-cells, membrane-bound GADe be- 
hayed like an intrinsic membrane protein, which could only 
be removed by detergent and not by salt, EDTA, or basic pH 
treatment (results not shown). Consistent with the results in 
B-cells, incorporation of radioactivity from 3H-palmitate 
was detected in membrane-bound but not soluble GAD65 in 
Sf9 cells (Fig. 3). 
Palmitoylation of  GAD,5 Is Hydroxylamine Sensitive 
Hydroxylamine atpH 8.0 is used as a method for a gentle 
removal of fatty acid from proteins (Omary and Trowbridge, 
1981; Magee et al., 1984) and can be used as a diagnostic 
test of a thioester- or ester-linked fatty acid. Incubations of 
3H-palmitic-labeled membrane-bound GAD~ on SDS-poly- 
acrylamide gels with hydroxylamine efficiently removed the 
radioactivity (Fig. 3, lanes 13 and 16) without loss of [35S]- 
methionine-labeled GAD~ (Fig. 3, lane 14). 
The fatty acid composition of the 3H-palmitate-labeled 
St9 cells was analyzed to assess whether palmitate had been 
converted to other fatty acids during the labeling period. 
Fatty acids were extracted from a membrane fraction pre- 
pared from the cells which contained 91% of the incorpo- 
rated label. The fatty acids were derivatized and analyzed by 
reverse phase high performance liquid chromatography (RP- 
HPLC). Fatty acid standards were cochromatographed to al- 
low the identification ofextracted fatty acids. 51% of the in- 
corporated label in SI9 cells was found as palmitic acid, 26 % 
was found as myristic acid, 10% was found as stearic acid, 
and 13% was found as minor unidentified peaks. (Fig. 4A). 
The label incorporated into GAD~s was identified by excis- 
ing radiolabeled GAD6s from gels, followed by hydrolysis 
under alkaline conditions. The released fatty acids were ana- 
lyzed by RP-HPLC and identified by cochromatography with 
standards. Only palmitic acid was detected in GADr ex- 
cised from gels (Fig. 4 B). Thus the incorporation of radio- 
activity into membrane-bound GAD~s in the presence of 3H 
palmitic acid represents palmitoylation f the protein and not 
incorporation of a palmitate-derived fatty acid confirming 
that the acylation of GAD65 is specific for palmitic acid. 
The analyses of membrane-bound and soluble forms of 
GAD65 suggested that the hydrophobic soluble and hydro- 
phobic membrane-bound GADe represent differential stages 
of a two-step osttranslational modification with hydropho- 
bic residues. Thus, attachment of the first hydrophobic resi- 
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Figure 4. Identification of palmitic acid as the lipid attached to 
GADs. (A) Reverse phase HPLC analysis of 3H-labeled fatty 
acids isolated from 3H-palmitic acid-labeled Sf9 cells. The posi- 
tions of myristate, palmitate, and stearate were identified by co- 
chromatography with standards. (B) Analysis of 3H-labeled fatty 
acids isolated from GAD65 purified from 3H-palmitic acid-labeled 
St9 ceils. The palmitate peak was identified by cochromatography 
with standards. The peak in the beginning of the chromatogram is 
nonderivatized fatty acids. 
due would result in soluble hydrophobic GAD65 and then 
palmitoylation of this form would result in the membrane- 
anchored form. 
To examine the possibility that the GAD65 autoantigen in 
B-cells is polyisoprenylatcd and that this modification is re- 
sponsible for the hydrophobicity of the $2 form, we tested 
whether 3H-mevalonatc was incorporated into GAD~ in ei- 
ther rat islet cells or Sf9 cells. The results of those experi- 
ments were negative, suggesting that a polyisoprenyl moiety 
is not a part of the hydrophobic modification and membrane 
anchoring of GADs5 (data not shown). Mevinolin, an inhib- 
itor of polyisoprenyl synthesis, also inhibited protein synthe- 
sis in islet cells, but did not inhibit hydrophobic modification 
and membrane anchoring of GADs5 significantly. The re- 
suits are consistent with the absence of the known COOH- 
terminal consensus sequences for polyisoprenylation, CAAX, 
CC, or CXC (Hancock et al., 1989; Khosravi-Far et al., 
1991) in GAD65 (Erlander et al., 1991). 
Spontaneous and 1line-dependent Release of GADo 
from Membranes 
In the initial phases of this study we had assessed whether 
GAD~ was membrane anchored by a PIG moiety (for re- 
view see Ferguson and Williams, 1988). In this type of mem- 
brane anchor, the diacylglycerol moiety of the PIG is in- 
serted into the lipid bilayer of membranes, but can be 
removed by the action of exogenous or endogenous phos- 
phatidyl inositol specific phospholipase C (PIPLC) (for re- 
view see Ferguson and Williams, 1988). 
Several lines of evidence, however, led to the conclusion 
that GAD~ is not modified by a PIG residue. First, no in- 
corporation of radioactivity into GAD65 was detected in the 
presence of 3H-inositol, 3H-ethanolamine, or 3H-glucos- 
amine which are building blocks of the PIG anchor. Second, 
if the soluble and membrane-bound forms of GADs5 differed 
by a PIG moiety, they would be expected to have different 
isoelectric points, which is not the case (Christgau et al., 
1991). 
Finally, we analyzed the ability of PIPLC to release 
GAD65 from washed islet cell membranes in the presence of 
buffers with and without components which either inhibit or 
stimulate the activity of PIPLC. The standard Hepes buffer 
A, which contains acocktail of proteolytic and other enzyme 
inhibitors, was used in control experiments. These experi- 
ments revealed that GAD65 was released from the mem- 
branes in all conditions except in buffer A, but equally with 
and without the addition of PIPLC. Taken together, the 
results suggest hat an endogenous enzyme, which is in- 
hibited in the conditions of Hepes buffer A, can cleave the 
membrane anchor and release GADes. Exogenously added 
Figure 5. Time-dependent re- 
lease of GAD65 from mem- 
branes. Washed membrane 
fractions prepared from rat is- 
lets homogenized in hypotonic 
conditions were resuspended 
and incubated in the presence 
or absence of protease inhibi- 
tors for the indicated length of 
time and then repelleted by ul- 
tracentrifugation at 265,000 g. 
The release of GADe5 was 
analyzed by immunoprecipi- 
tation of supernatants, SDS- 
PAGE, and immunoblotting 
with the 1266 COOH-terminal 
peptide antibody. GAD65 released during a 60-min incubation without enzyme inhibitors was subjected to a TX-114 phase separation t  
analyze the distribution into detergent (d) and aqueous (a) phases (lanes 9 and 10). 
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Figure 6. Absence of hydrophobic and membrane anchoring moieties in a 55-kDC-terminal trypsin fragment of GAD65. (A) Tx-ll4 deter- 
gent phase was prepared from a cytosol and membrane fraction isolated from rat islets homogenized in hyp to ic conditions. Thedetergent 
phases were incubated with and without trypsin followed by a new TX-114 phase separation. The detergent phase (d) and aqueous phase 
(a) from this last separation were analyzed by SDS-PAGE followed by Western blotting and immunostaining with the COOH-terminal 
peptide antiserum 1266. (B) Washed membranes were prepared from atislets homogenized in hypotonic conditions resuspended and incu- 
bated with and without trypsin followed by ultracentrifugation at 265,000 g. The supernatants and TX-114 extracts of residual membranes 
were subjected to phase separation and aqueous (a) and detergent ( ) phas s were analyzed by SDS-PAGE, Western blotting, and immuno- 
staining with the COOH-terminal peptide antiserum 1266. 
PIPLC does not, however, affect his release, consistent with 
the membrane anchor not having the properties of a PIG 
residue. 
To analyze the release of GAD65 further, washed mem- 
branes prepared from islets, were incubated with and with- 
out enzyme inhibitors for different periods of time. No re- 
lease of GAD65 from membranes was detected in the 
presence of enzyme inhibitors. In the absence of enzyme in- 
hibitors, however, amphiphilic GAD65 was released from 
membranes in a time-dependent fashion (Fig. 5), suggesting 
that islets contain an enzyme activity which can cleave the 
GAD~ membrane anchor, but not the hydrophobic moiety 
of the soluble $2 form. GAD65 released from membranes of
islet cells did partition into the TX-114 detergent phase (Fig. 
5, lanes 9 and 10, see also Fig. 6 B), suggesting that the re- 
lease represents a conversion of the firmly membrane an- 
chored form to the soluble but still hydrophobic $2 form. In 
addition a 55-kD hydrophilic fragment of GAD65 was de- 
tected in the fraction released from the membrane in some 
experiments (Fig. 5, lane 10), suggesting either that the pro- 
tein can also be released from the membrane by proteolytic 
cleavage or that released GAD6~ is susceptible to proteo- 
lytic cleavage. 
Localization of the Hydrophobic 
Membrane Anchoring Region of GADs5 to a Fragment 
at the NHz Terminal 
We addressed the localization of the hydrophobic residue(s) 
and membrane anchor in the GAD65 protein by analyzing 
the hydrophobicity of fragment(s) generated by mild trypsin 
digestion of the hydrophobic soluble and membrane forms 
of GAD~. Islets were homogenized in a hypotonic buffer 
and cytosol and membrane fractions prepared. The am- 
phiphilic proteins in both fractions were purified into the de- 
tergent phase of TX-114 and incubated with and without 
trypsin followed by a new TX-114 phase separation. The de- 
tergent and aqueous phases from this last phase separation 
were analyzed by SDS-PAGE and immunoblotting using an 
antiserum raised against a 19-amino acid COOH-terminal 
peptide of the larger brain form of GAD (GAD67). Because 
of an extensive homology at the COOH terminus between 
GADs7 and GAD65 (Erlander et al., 1991), this antiserum 
recognizes both forms equally well. The results are shown 
in Fig. 6 A. Trypsin digestion resulted in a 55-kD fragment 
in both the soluble and the particulate fraction, which was 
recognized by the COOH-terminal peptide antibody, and 
therefore contains the COOH-terminal part of the GAD mol- 
ecule. 
In incubations without rypsin, GADs5 from both soluble 
and particulate fractions partitioned into the TX-114 deter- 
gent phase. The 55-kD fragment from both fractions was, 
however, exclusively detected in the aqueous phase and had 
thus lost i s hydrophobic moiety (Fig. 6 A). The results ug- 
gest that the hydrophobic residue(s) in both the soluble and 
membrane anchored form reside in a 9-10-kD fragment at 
the NH2-terminus. 
We next analyzed whether trypsin was able to release 
membrane-bound GADs. The particulate fraction was 
resuspended and washed three times in TBS to remove 
loosely associated proteins, and then incubated with and 
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without rypsin for 1 h. Released proteins were analyzed by 
western blotting (Fig. 6 B). Although a minor fraction of 
full-length amphiphilic GAD6~ is released spontaneously 
from the membranes in those conditions (Fig. 6 B, lanes 1 
and 2), the majority of GAD65 remains membrane-anchored 
(Figure 6 B, lanes 5 and 6). In experiments containing tryp- 
sin, GAD6~ was released from the membranes as a 55-kD 
hydrophilic COOH-terminal fragment (Fig. 6 B), indicating 
that the membrane-anchoring moiety resides in a 9-10-kD 
fragment at the NH2-terminus. Attempts to detect he NH2- 
terminal fragment following trypsin digestion by immuno- 
blotting were unsuccessful. Thus, a small (9-10 kD) fragment 
was not detected by immunostaining with the polyclonal an- 
tibody $3 nor with the monoclonal ntibody GAD6. It is con- 
ceivable that neither antibody reacts with the NH2-terminal 
fragment or that the fragment is further digested into small 
fragments by trypsin since it contains everal basic residues 
(Erlander et al., 1991). In attempts to detect he NH2-ter- 
minal fragment, the trypsin experiments described above 
and shown in Fig. 6 A and B were repeated using 3H-pal- 
mitic acid-labeled Sf9 cells and analysis by SDS-PAGE fol- 
lowed by both fluorography ofgels as well as immunostaining 
of Western blots using the COOH-terminal peptide antibody 
1266. In those experiments following trypsin treatment, as 
expected 3H-palmitic acid labeling was only detected in re- 
sidual particulate full-length GAD65 but not in the 55 kD 
fragment (results not shown). A residual 9-10 kD fragment 
was detected in fluorograms of total extracts of membranes 
treated with trypsin but not in membranes from control incu- 
bations and may represent the 3H-palmitoylated NH.,-termi- 
nal fragment of GAD65 (not shown). Consistently this frag- 
ment did not stain with the 1266 antibody on Western blots. 
In sum the experiments with trypsin provide evidence that 
the hydrophobic modification and membrane anchoring of 
GAD65 takes place in the NH2-terminal 9-10-kD part of the 
protein. 
Discussion 
In pancreatic slets GAD65 undergoes membrane anchoring 
in a process that involves a two-step modification. The first 
step results in a hydrophobic molecule which is soluble or 
has a low membrane avidity. The second step results in a firm 
membrane anchoring. (Christgau et al., 1991). The results 
described herein show that the second step involves a hy- 
droxylamine-sensitive palmitoylation, and results in a mole- 
cule with intrinsic membrane protein properties. GAD~ can 
be released from islet cell membranes in a time-dependent 
manner, in a process in which enzyme activity is implicated, 
suggesting that the second step is reversible and that GAD~ 
may be flexible in its membrane-anchoring properties. Im- 
munogold EM analysis with GAD antibodies how clear 
labeling of the membrane of small vesicles in pancreatic 
~-cells, which are similar in size to synaptic-like microvesi- 
cles (Reetz et al., 1991) and clearly distinct from the insulin- 
containing secretory vesicles in those cells. The EM results 
shown here are consistent with data from immunohistochem- 
ical analysis of GAD and GABA in ~-cells and neurons by 
confocal microscopy (Sorenson et al., 1991; Reetz et al., 
1991), which show localization of both to a vesicular com- 
partment. This compartment was shown to be concentrated 
in nerve terminals and in the distal portions of neurite-like 
extensions inB-cells, and was tentatively identified as synap- 
tic vesicles in neurons and synaptic-like microvesicles in
/3-cells by colocalization with synaptophysin (Reetz et al., 
1991). Based on the confocal microscopy data (Sorenson et 
al., 1991; Reetz et al., 1991), on the electron microscopic 
analysis hown here, and on the demonstration f the intrin- 
sic membrane protein properties of GAD65 (Christgau et al., 
1991, this study, and unpublished results) we conclude that 
the membrane-anchored form of GAD65 is localized to the 
membrane of synaptic-like microvesicles containing GABA 
in ~-cells and synaptic vesicles in neurons. A previous im- 
munogold EM study using embedded brain and islet-cell 
homogenates (Reetz et al., 1991) has shown concentrations 
of GAD immunoreactivity in the proximity of synaptic vesi- 
cles in brain and synaptic-like microvesicles containing 
GABA in pancreatic/3-cells. However this study did not re- 
veal an association of GAD with those microvesicles. This 
previous failure to detect GAD in synaptic vesicle mem- 
branes by immunogold EM of homogenized islets, and by 
subcellular f actionation (Reetz et al., 1991) is most likely 
because of the reversible nature of the membrane anchoring 
we have now documented. In fact, preparation ofmembranes 
in the absence of enzyme inhibitors and at elevated tempera- 
tures or at weak alkaline pH can result in the majority of 
GAD6~ being recovered as soluble (our unpublished results). 
Furthermore, ven in the absence of trypsin a fraction of 
GAD is often recovered as a 55-kD soluble and hydrophilic 
COOH-terminal fragment (Christgau et al., 1991; and this 
study), suggesting that GAD may also be released from mem- 
branes by proteolytic leavage during homogenization a d/ 
or further fractionation of cells. 
The characteristics of the posttranslational modifications 
and the subcellular and amphiphilic properties of the differ- 
ent forms of GAD65 resemble in many ways those of the ras 
proteins (Hancock et al., 1989) and the rab GTP-binding 
proteins (for review see Balch, 1990), all of which exist both 
in a soluble hydrophobic and a membrane-bound hydropho- 
bic form, with intrinsic membrane protein properties. The 
latter group includes the rab 3A and 3B proteins which are 
also found in the membrane ofsynaptic vesicles (for review 
see Siidhof and Jahn, 1991). The posttranslational modifica- 
tion and membrane anchoring of the ras and the rab proteins, 
however, involves isoprenylation a d carboxymethylation at 
the COOH terminus which contains either a CAAX, CXC, 
or CC motif (Hancock et al., 1989; Farnsworth et al., 1991; 
Kohsravi-Far et al., 1991). GAD65 does not contain an iso- 
prenylation motif at the COOH terminus (Erlander et al., 
1991) and does not seem to undergo this modification. Rather, 
the first modification of GAD6s appears to involve a differ- 
ent mechanism. The second modification of GAD65, how- 
ever, does resemble that of some of the ras proteins in being 
a palmitoylation that results in firm membrane anchoring. 
Furthermore, as for ras proteins (Magee et al., 1987), the 
membrane anchoring is reversible. 
Interestingly, GAD6s can be posttranslationally modified, 
palmitoylated, and membrane anchored in insect Sf9 cells 
and in cos cells (our unpublished results), which apparently 
do not contain synaptic-like microvesicles. This result sug- 
gests that the posttranslational modification of GAD~ and 
its targeting to synaptic vesicles are separate vents. Post- 
translational modification and membrane anchoring may 
take place before budding of membrane vesicles from the 
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Golgi complex. Then perhaps the final targeting of the 
membrane-anchored form to synaptic-like microvesicles in
/3-cells and synaptic vesicles in neurons depends on interac- 
tion with components of synaptic vesicles which are absent 
in Sf9 and cos cells. 
Relevance for Function 
In cerebral cortex, both GABA and glutamate have been 
shown to be stored in synaptic vesicles. It is however unclear 
whether those amino acids reside in the same or different 
vesicles (Burger et al., 1991). Membrane-anchored GAD65 
may therefore be localized so as to provide GABA directly 
to the vesicle that secretes it, thereby coordinating enzymatic 
activity and GABA secretion. An important question is 
whether GAD65 resides in the lumen or at the cytosolic face 
of the vesicles. In the first case the enzyme would be in the 
immediate proximity of glutamate and/or GABA. It is nota- 
ble that GAD~ lacks a known signal sequence (Erlander et 
al., 1991) and thus would require a novel transport mecha- 
nism to achieve a luminal ocalization. If GAD is anchored 
at the cytoplasmic face, which seems most likely, it could as- 
sociate with its substrate glutamate and release its product 
GABA in coordination with their transporters in the mem- 
brane of synaptic vesicles (Burger et al., 1991 and references 
therein). 
In rat pancreatic/3-cells membrane attachment is the ex- 
clusive property of the predominant GAD65 form and is not 
detected in the minor nonallelic protein, GAD67, which re- 
mains hydrophilic and soluble throughout its lifespan (Christ- 
gau et al., 1991). GAD65 and GAD67 are most divergent in 
the first 100 amino acids but share in high degree of ho- 
mology in the remainder of the molecules (Erlander et al., 
1991). Taking advantage of a trypsin sensitive hot spot, we 
have now shown evidence that the area of hydrophobic modi- 
fication and membrane anchoring of GAD65 resides in the 
9-10-kD fragment at the NHz terminus where this protein 
differs most significantly from GAD67. 
The reason why two genes encoding distinct versions of 
this enzyme have developed and why/%cells preferably ex- 
press GAD65 is not known. GAD67 binds the coenzyme 
pyridoxal phosphate more tightly and is less dependent on 
exogenous coenzyme than GAD65, which is mainly found in 
the apoenzyme form (Martin et al., 1991). Accordingly 
GAD65 activity is more sensitive to pyridoxal phosphate 
levels than GAD67 (Kaufman et al., 1991). In neurons 
GAD65 has been shown to be predominantly ocalized to 
nerve endings (Henry and Tappaz 1991; Kaufman et al., 
1991) consistent with its localization i  the membrane ofsyn- 
aptic vesicles which concentrate proximal to the synaptic 
membrane ,  GAD67 is however predominantly ocalized in 
the cell bodies of neurons (Kaufman et al., 1991; Henry and 
Tappaz, 1991). It is conceivable that the localization of the 
pyridoxal phosphate inducible form, GAD65, to the mem- 
brane of the vesicles that store and secrete its product GABA 
has a regulatory purpose and serves to accommodate sudden 
increases in GABA demand. Interestingly there are examples 
of other enzymes involved in the synthesis of transmitters 
that are anchored to the membrane ofgranules that store and 
secrete them. Thus tyrosine hydroxylase, the initial and rate- 
limiting enzyme in the biosynthesis of the catecholamines, 
and dopamine/3-hydroxylase, the final enzyme in the synthe- 
sis of norepinephrine, exist in both soluble and membrane- 
bound forms and the latter have been localized to the mem- 
brane of chromaffin granules in the adrenal medulla (Kuhn 
et al., 1990; Bon et al., 1991). 
Relevance for Autoimmunity 
The correlation in autoimmunity oward pancreatic ~-cells 
and brain neurons is remarkable, specially as it is revealed 
in the development of autoantibodies which recognize the 
same antigen, the 64-kD form of glutamic acid decarboxy- 
lase. A second nonallelic form of this enzyme ncoded by 
a distinct gene, GAD67, is apparently only of secondary im- 
portance. GAD67 lacks the primary epitopes which are anti- 
genic in SMS (Baekkeskov et al., 1990), and evidences a 
lower incidence of specific autoantibodies in IDDM (our un- 
published results). It is therefore provocative that these two 
proteins are clearly distinguished by an NH2-terminal re- 
gion which determines hydrophobic modification, subse- 
quent palmitoylation, and consequent membrane anchoring 
and subcellular localization. Only GADts has these two 
posttranslational modifications that confer hydrophobicity, 
membrane attachment, and association with microvesicles. 
It is of note that palmitoylated influenza peptides induce po- 
tent cytotoxic T-cell responses in vivo whereas their non- 
palmitoylated counterparts do not (Deres et al., 1989). Per- 
haps one of the posttranslational modifications, or the 
selective localization of GAD65 into a membrane compart- 
ment that is secretory in nature is instrumental for its role 
as an autoantigen i  these two diverse but coinciding autoim- 
mune diseases. 
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